CLINICAL AND LABORATORY STUDIES OF MALIGNANT LYMPHOMAS

恶性淋巴瘤的临床和实验室研究

• 批准号: 3093545
• 负责人: SAUL A ROSENBERG
• 金额: $ 199.01万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-04-01 至 1991-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3093545
• 关键词: combination cancer therapy; lymphoma; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer radiation therapy; pediatric neoplasm /cancer

Basic scientists and clinicians will collaborate to study the biology of human lymphoma cells, improve the cure rate while decreasing the toxidity of current therapy for lymphoma, and develop new modalities of treatment. Human lymphoma cells will be phenotyped with monoclonal antibodies, and nucleic acid probes. They will be established as cell lines in tissue culture. Their tissue homing properties will be examined. A series of controlled clinical trials will be performed for adults and children with all stages of Hodgkin's disease. The results of our ongoing clinical trials will be used to design new protocols of radiotherapy and chemotherapy. Outcome data will be accumulated and anlyzed in terms of response rate and cure with special attention to the long-term morbidity of treatment. New approaches to statistical methods will be studied. Patients with non-Hodgkin's lymphomas will be studied with sensitive genetic probes and monoclonal antibodies to determine their disease stage, treatment response, recurrence, clonality and their candidacy for novel therapies with monoclonal antibodies, lymphokines and interferon.

基础科学家和临床医生将合作研究 人淋巴瘤细胞，提高治愈率，同时降低毒性 当前用于淋巴瘤的治疗，并发展出新的治疗方式。 人淋巴瘤细胞将用单克隆抗体表型，并 核酸探针。 它们将被确定为组织中的细胞系 文化。 他们的组织归巢特性将进行检查。 成人将进行一系列对照临床试验，并 霍奇金氏病的各个阶段的孩子。 我们正在进行的结果 临床试验将用于设计放疗的新方案和 化学疗法。 结果数据将被累积并用 应答率和治愈，特别注意 治疗。 将研究统计方法的新方法。 将对非霍奇金淋巴瘤患者进行敏感研究 遗传探针和单克隆抗体以确定其疾病阶段， 治疗反应，复发，克隆性及其对新颖的候选人资格 单克隆抗体，淋巴细胞和干扰素的疗法。